Aller au contenu principal
Fermer
  2. Aide
  2. Aide
Nikkei 225
52 221,71
-0,36%
Indices
Chiffres-clés
+ fortes hausses et baisses SBF 120

Transgene: Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
information fournie par Boursorama CP 10/03/2021 à 17:45

2020 Full-year results and business update

­- TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology - First data expected in 4Q 2021

­- TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data

­- BT-001: the first candidate from the Invir.IO(TM) platform has entered the clinic

­- Financial visibility until 2022 following the partial sale of the stake in Tasly BioPharmaceuticals in 2020

Conference call in English scheduled today at 6:00 p.m. CET - Video conference in French on March 10 at 10:00 a.m. CET (details at the end of the release)

.../...

Valeurs associées

TRANSGENE
1,360 EUR Euronext Paris +1,49%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...

Pages les plus populaires

L'offre BoursoBank